tbuckley/cabot-search huggingface dataset:
Estrogen and prolactin upregulate zinc transports and zinc uptake in the prostate cancer cell lines
Authors: Ariana Stir, Brittani Lane, Maureen Watson, Omar Bagasra
Journal: Cancer Research (2006)

3273  The genetic/molecular basis of the development and progression of prostate cancer is largely unidentified. The most consistent and persistent distinguishing characteristic of malignant prostate is the inability of the malignant epithelial cells to accumulate zinc. A key factor in the malignant process is the mechanism that results in this inability of the neoplastic prostate cell to accumulate zinc. Recent studies identified ZIP1 (SLC39A1) as an important zinc transporter involved in the uptake and accumulation of zinc by prostate cells: up-regulation of hZIP1 in prostate cells increases zinc accumulation, which inhibits cell growth and increases net citrate production; down-regulation of hZIP1 decreases zinc accumulation in prostate cells 1-5. The down-regulation of hZIP1 transporter expression appears to be an essential factor in the development and progression of malignant prostate cells. We have shown that hZIP1 gene expression, which is expressed in normal peripheral zone glandular epithelium (the zone where prostate cancer occurs most often), is down-regulated in adenocarcinomatous glands. Correspondingly, the zinc level is depleted in the malignant glands. Down-regulation of hZIP1 and consecutive zinc depletion is a critical early event in the development of prostate malignancy. The intracellular zinc concentration in situ was measured using the zinc indicator dye Newport Green DCF (Molecular Probes, Eugene, OR). In our studies, three steroid hormones-testosterone, beta-estrodial and prolactin-at varying concentrations (ranging from 1ng/ml to 10,000ng /ml and combinations) were tested on five different cell lines, each exhibiting different characteristics with regards to their dependency on various hormones. The five cell lines utilized were: 1) LnCAP, PC3, RWPE-1, RWPE-2 and CA-HPV-10. After exposure to the three different hormones separately or in combination overnight or for two hours, the zinc uptake of the prostate cells was assayed by utilizing zinc indicators. The intracellular levels of zinc were measured by an Elisa based reader and by fluorescent microscopic visualization. The hZIP1, hZIP2, hZIP4 genes expression were analyzed by performing RT-PCR using RNA extracted from hormone-treated cells as a template. We have determined that: i) high concentrations of testosterone drastically decrease the zinc uptake, ii) a combination of low testosterone and relatively high estrogen and high prolactin increases zinc uptake in prostate cell lines and the same combination gives a two fold higher expression of both hZIP1 and hZIP2. Implications of a potential therapy or prevention for prostate cancer utilizing a zinc supplement plus a combination of hormones will be presented.
Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
Authors: N. Freemantle, G.K. Abou-Alfa, A.-L. Cheng, R.K. Kelley, V. Valcheva, F. Benzaghou, P. Mollon
Journal: Annals of Oncology (2019)
Self-assembled small molecule natural product gel for drug delivery: a breakthrough in new application of small molecule natural products
Authors: Kangkang Zhi, Jiacheng Wang, Haitian Zhao, Xin Yang
Journal: Acta Pharmaceutica Sinica B (2019)

Natural products, as a gift of nature to humanity, have long been used as drugs or pharmacological actives to help people cure various diseases. Yet we still know comparatively little about their ability to be materials. In recent years, some small molecule natural products isolated from traditional Chinese medicines have been found to have new features, namely, self-assembly to form gels (i.e., natural product gels, NPG). However, the application development of these natural products is seriously lacking, which greatly weakens their practical value and delays the maturity of the field. Here, a series of self-assembled triterpenoid natural products are used as materials (gel scaffolds) to construct drug delivery systems. Surprisingly, these NPG not only exhibit the excellent self-healing, controlled gelation, good safety and sustained release, but also achieve synergistic treatment of tumors through bioactive natural products. Compared with non-bioactive gel scaffolds, NPG scaffolds show great advantages in tumor therapy, including optimal tumor inhibition, preferable health, better body recovery, stronger immune function, less toxic side effects and longer survival. The successful construction of NPG scaffolds not only takes full advantage of the self-assembled natural products, but also takes an important step in the development of new applications for natural products.
Myelin-specific CD8+ T cells exacerbate brain inflammation in CNS autoimmunity
Authors: Catriona A. Wagner, Pamela J. Roqué, Trevor R. Mileur, Denny Liggitt, Joan M. Goverman
Journal: Journal of Clinical Investigation (2019)

Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the CNS. Although CD4+ T cells are implicated in MS pathogenesis and have been the main focus of MS research using the animal model experimental autoimmune encephalomyelitis (EAE), substantial evidence from patients with MS points to a role for CD8+ T cells in disease pathogenesis. We previously showed that an MHC class I-restricted epitope of myelin basic protein (MBP) is presented in the CNS during CD4+ T cell-initiated EAE. Here, we investigated whether naive MBP-specific CD8+ T cells recruited to the CNS during CD4+ T cell-initiated EAE engaged in determinant spreading and influenced disease. We found that the MBP-specific CD8+ T cells exacerbated brain but not spinal cord inflammation. We show that a higher frequency of monocytes and monocyte-derived cells presented the MHC class I-restricted MBP ligand in the brain compared with the spinal cord. Infiltration of MBP-specific CD8+ T cells enhanced ROS production in the brain only in these cell types and only when the MBP-specific CD8+ T cells expressed Fas ligand (FasL). These results suggest that myelin-specific CD8+ T cells may contribute to disease pathogenesis via a FasL-dependent mechanism that preferentially promotes lesion formation in the brain.
CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors
Authors: E.S. Antonarakis, P Isaacsson Velho, N. Agarwal, V Sacristan Santos, B.L. Maughan, R. Pili, N. Adra, C.N. Sternberg, P.J. Vlachostergios, S.T. Tagawa, A.H. Bryce, A.L. McNatty, Z.R. Reichert, R. Dreicer, O. Sartor, T.L. Lotan, M. Hussain
Journal: Annals of Oncology (2019)
Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
Authors: N. Frost, J. Kollmeier, D. Pultermann, A. Tessmer, A. Schmittel, B. Schmidt, C. Grah, M. de Wit, D. Misch, T. Blum, N. Suttorp, C. Grohe
Journal: Annals of Oncology (2019)
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
Authors: Myung-Ju Ahn, Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Dong-Wan Kim, Yun-Gyoo Lee, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Jong-Seok Lee, Young Joo Min, Jin-Soo Kim, Sung Sook Lee, Hye Ryun Kim, Min Hee Hong, Jin Seok Ahn, Jong-Mu Sun, Heung Tae Kim, Dae Ho Lee, Sohee Kim, Byoung Chul Cho
Journal: The Lancet Oncology (2019)
Diastolic Wall Strain can Noninvasively Predict Hemodynamic Deterioration Unassociated with Systolic Dysfunction in Hypertensive Hearts
Authors: Omori Yosuke, Sakata Yasushi, Mano Toshiaki, Ohtani Tomohito, Takeda Yasuharu, Tamaki Shunsuke, Kamimura Daisuke, Higashimori Mitsuru, Kaneko Makoto, Yamamoto Kazuhiro
Journal: Circulation (2009)
How the weather affects the pain of citizen scientists using a smartphone app
Authors: William G. Dixon, Anna L. Beukenhorst, Belay B. Yimer, Louise Cook, Antonio Gasparrini, Tal El-Hay, Bruce Hellman, Ben James, Ana M. Vicedo-Cabrera, Malcolm Maclure, Ricardo Silva, John Ainsworth, Huai Leng Pisaniello, Thomas House, Mark Lunt, Carolyn Gamble, Caroline Sanders, David M. Schultz, Jamie C. Sergeant, John McBeth
Journal: npj Digital Medicine (2019)

Patients with chronic pain commonly believe their pain is related to the weather. Scientific evidence to support their beliefs is inconclusive, in part due to difficulties in getting a large dataset of patients frequently recording their pain symptoms during a variety of weather conditions. Smartphones allow the opportunity to collect data to overcome these difficulties. Our study
Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer
Authors: M.A.C. Vermunt, J.M. Janssen, G.L. Vrijenhoek, H.G. van der Poel, B. Thijssen, J.H. Beijnen, B. van Triest
Journal: Annals of Oncology (2019)
Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring dna repair deficiencies
Authors: C.E. Heilig, D. Hübschmann, H.-G. Kopp, K.H. Metzeler, S. Richter, B. Hermes, N. von Bubnoff, T. Kindler, J. Siveke, S. Wagner, S. Ochsenreither, H. Süße, B. Brors, A. Benner, D. Jäger, C. Von Kalle, H. Glimm, S. Gröschel, S. Fröhling, R.F. Schlenk
Journal: Annals of Oncology (2019)
Adjuvant chemotherapy in elderly breast cancer patients: Pattern of use and impact on overall survival
Authors: A. Berthelot, A. De Nonneville, J.-M. Classe, M. Cohen, F. Reyal, C. Mazouni, M.P. Chauvet, A. Martinez, N. Chopin, E. Daraï, C. Coutant, R. Rouzier, A.-S. Azuar, P. Guimbergues, C Tunon De Lara, R. Villet, M. Bannier, A. Gonçalves, G. Houvenaeghel
Journal: Annals of Oncology (2019)
Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours
Authors: J.J. Luke, L. Fong, K. Chung, A.W. Tolcher, K. Kelly, A. Hollebecque, C. Le Tourneau, V. Subbiah, F. Tsai, S. Kao, P. Cassier, M. Khasraw, K. Allaire, F. Fan, H. Fang, M. Patel, W. Henner, J. Hayflick, M. McDevitt, F. Barlesi
Journal: Annals of Oncology (2019)
Early palliative care in advanced cancer: Is it really effective?
Authors: R. Gómez Bravo, J.C. Sánchez González, B. Núñez García, A.M. Morito Aguilar, F. García Recio, A. Ruano Raviña, M. Méndez García, B. Cantos, M. Provencio
Journal: Annals of Oncology (2019)
Genomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT)
Authors: A. Chen, S. Kummar, S.S. Khan, N. Moore, L. Rubinstein, G O’Sullivan Coyne, Y. Zhao, A. Palmisano, P. Williams, V. Datta, D. Sims, C. Karlovich, C.-J. Lih, K.P.S. Raghav, F. Meric-Bernstam, S. Leong, S. Waqar, N. Takebe, E. Sharon, J. Doroshow
Journal: Annals of Oncology (2019)
Understanding the Global Prevalence of Hypertension in Children and Adolescents
Authors: Stephen R. Daniels
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
First-line single-agent cetuximab in patients with advanced colorectal cancer
Authors: A. Pessino, S. Artale, A. Guglielmi, S. Sciallero, G. Fornarini, I. C. Andreotti, S. Mammoliti, G. Marrapese, S. Siena, A. Sobrero
Journal: Journal of Clinical Oncology (2006)

3553 Background: The most relevant recent advance in the treatment of metastatic colorectal cancer is the fact that cure is still possible under very selected conditions. However the goal of chemotherapy remains palliative in the great majority of patients, justifying less toxic innovative approaches in so- called “window of opportunity trials”. We have pursued this idea in a phase II study of cetuximab monotherapy in chemo-naive patients with advanced colorectal cancer beyond any possibility of curative resection. Methods: Patients with non-resectable metastatic colorectal cancer (at least two metastatic sites and/or otherwise inoperable metastatic disease) were treated with cetuximab (400 mg/m 2 week 1 and 250 mg/m 2 weekly thereafter) until progressive disease (PD) or unacceptable toxicity. The primary end-point was objective response; secondary end-points were: stable disease, time to treatment failure and time to progression. According to Simon’s two-stage design, the number of responses/patients to stop the trial was 0/10 for stage 1 and 3/29 for stage 2. Results: Of the 44 patients screened, 42 (97%) had EGFR-expressing tumors. Thirty-nine patients (median age: 69) initiated the treatment. Two had grade 3 allergic reactions to cetuximab at the first administration leading to treatment discontinuation. The most common adverse event was skin toxicity, which occurred in 90% of the patients ( 31% grade 2, 10 % grade 3). We observed 1 complete response, 3 partial responses, 13 stable diseases (5 of which were minor responses), and 22 PD. The duration of the 4 responses were 12, 9, 9 and 6 months. Median time to progression was 2.0 months. Conclusions: The study is negative because the response rate is low. However, the duration of benefit in the few responding patients is such that it is imperative to find the molecular determinants of cetuximab activity in these cases. [Table: see text]
Consistency of ESMO-MCBS scores with drug access recommendations in Catalonia
Authors: C. Salazar, M. Obach, J.M. Fontanet, G. Garrido, A. Feliu, M. Riba, M. Umbria, M. Gasol, A. Prat, A. Vallano, C. Pontes
Journal: Annals of Oncology (2019)
Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast cancer (TNBC)
Authors: A. Noske, J. Ammann, D.-C. Wagner, C. Denkert, A. Lebeau, P. Sinn, H.-H. Kreipe, G. Baretton, K. Steiger, M. Kiechle, S. Hieke-Schulz, W. Roth, W. Weichert
Journal: Annals of Oncology (2019)
Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting
Authors: D.R. Camidge, B.J. Solomon, E. Felip, B. Besse, A. Bearz, S. Peters, F. Toffalorio, A. Abbattista, H. Thurm, G. Peltz, R. Wiltshire, A.T. Shaw
Journal: Annals of Oncology (2019)
Health impact assessment of Brexit: it’s not too late
Authors: Liz Green, Nerys Edmonds, Sumina Azam, Mark A Bellis
Journal: BMJ (2019)

van Schalkwyk and colleagues advocate for health and wellbeing to be considered as a priority in Brexit decision making processes.1 Health impact assessment is a valuable, evidence based tool through which to view and understand the potential health implications of Brexit. The authors say that this task might be difficult, maybe insurmountable. But we published a …
Gefitinib along with methotrexate as palliative therapy in PS 3 and above in metastatic squamous cell carcinoma head and neck cancer patients
Authors: V.S. Dusi, D.S. Pallanki, S.S. Nirni, S.S. Atilli, V.V. Andra, V.M. Ch
Journal: Annals of Oncology (2019)
CD103hi Treg cells constrain lung fibrosis induced by CD103lo tissue-resident pathogenic CD4 T cells
Authors: Tomomi Ichikawa, Kiyoshi Hirahara, Kota Kokubo, Masahiro Kiuchi, Ami Aoki, Yuki Morimoto, Jin Kumagai, Atsushi Onodera, Naoko Mato, Damon J. Tumes, Yoshiyuki Goto, Koichi Hagiwara, Yutaka Inagaki, Tim Sparwasser, Kazuyuki Tobe, Toshinori Nakayama
Journal: Nature Immunology (2019)
Abstract 16615: A Rare MEGF8 Variant is Involved in the Genetic Risk for Transposition of the Great Arteries
Authors: Anne Moreau de Bellaing, Kylia Williams, Sally Li, Abha S Bais, Cullen B Young, Cecilia W Lo
Journal: Circulation (2018)

Introduction: Transposition of the great arteries (TGA) is one of the most common neonatal heart defects with a prevalence of 0.2 per 1,000 live births. Although some studies have suggested lateral...
Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
Authors: R.W. Naumann, A. Oaknin, T. Meyer, J.M. Lopez-Picazo, C. Lao, Y.-J. Bang, V. Boni, W.H. Sharfman, J.C. Park, L.A. Devriese, K. Harano, C.H. Chung, S.L. Topalian, K. Zaki, T. Chen, J. Gu, B. Li, A. Barrows, A. Horvath, K.N. Moore
Journal: Annals of Oncology (2019)
Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes
Authors: Louis Potier, Ronan Roussel, Michel Marre, Petter Bjornstad, David Z. Cherney, Ray El Boustany, Frédéric Fumeron, Nicolas Venteclef, Jean-François Gautier, Samy Hadjadj, Kamel Mohammedi, Gilberto Velho
Journal: Diabetes Care (2019)

OBJECTIVE Diabetes is the leading cause of nontraumatic lower-extremity amputations (LEAs). Identification of patients with foot ulcers at risk for amputation remains clinically challenging. Plasma copeptin, a surrogate marker of vasopressin, is associated with the risk of cardiovascular and renal complications in diabetes. RESEARCH DESIGN AND METHODS We assessed the association between baseline plasma copeptin and risk of LEA during follow-up in four cohorts of people with type 1 (GENESIS, n = 503, and GENEDIAB, n = 207) or type 2 diabetes (DIABHYCAR, n = 3,101, and SURDIAGENE, n = 1,452) with a median duration of follow-up between 5 and 10 years. Copeptin concentration was measured in baseline plasma samples by an immunoluminometric assay. RESULTS In the pooled cohorts with type 1 diabetes (n = 710), the cumulative incidence of LEA during follow-up by increasing tertiles (tertile 1 [TER1], TER2, and TER3) of baseline plasma copeptin was 3.9% (TER1), 3.3% (TER2), and 10.0% (TER3) (P = 0.002). Cox regression analyses confirmed the association of copeptin with LEA: hazard ratio (HR) for 1 SD increment of log[copeptin] was 1.89 (95% CI 1.28–2.82), P = 0.002. In the pooled cohorts of type 2 diabetes (n = 4,553), the cumulative incidence of LEA was 1.1% (TER1), 2.9% (TER2), and 3.6% (TER3) (P &amp;lt; 0.0001). In Cox regression analyses, baseline plasma copeptin was significantly associated with LEA: HR for 1 SD increment of log[copeptin] was 1.42 (1.15–1.74), P = 0.001. Similar results were observed in the cohort with type 2 diabetes for lower-limb revascularization (HR 1.20 [95% CI 1.03–1.39], P = 0.02). CONCLUSIONS Baseline plasma copeptin is associated with cumulative incidence of LEA in cohorts of people with both type 1 and type 2 diabetes and may help to identify patients at risk for LEA.
Abstract 8611: The Early Calcification in Neointima of in Stent Restenosis
Authors: Yoshiaki Kawase, Junko Honye, Munenori Okubo, Taiji Miyake, Sigeshi Kamikawa, Hideaki Ota, Hiroki Kondo, Kunihiko Tsuchiya, Hitoshi Matsuo, Ik-Kyung Jang, Katsumi Ueno
Journal: Circulation (2011)

Background: It has been proven that homogeneous neointima in the early phase after stent implantation transforms into atherosclerotic tissue in their late phase and develops calcification, but there are several cases that demonstrate calcification in the neointima of in stent restenosis (CISR) in their early phase (&lt;=365days). Purpose: To elucidate the timing, prevalence, and extent of CISR. Method: The images of intravascular ultrasound (IVUS) taken between 6/30/2009 to 2/28/2011 were analyzed. The patients were divided into two groups depending on the follow up period: (less than 365 days or greater than 365 days) Result: A total of 169 IVUS images were analyzed. In general, patient with CISR had higher serum creatinine levels (3.3±3.4 mg/dl vs 1.4±1.6 mg/dl; p&lt;0.001) with a higher percentage of hemodialysis patients (36% vs 6%; p&lt;0.0001) and longer follow up time (2136±173 days vs 796±1129 days; p&lt;0.001) than patients without CISR. The patients who developed CISR during the early follow up period (&lt;=365 days) were almost exclusively those on hemodialysis (88%) and accounted for 8.2% of the patients with early follow up period. Conclusion: The development of CISR within the early follow up period (&lt;=365days) was observed in 8.2% of patients, most of whom required hemodialysis.
Breast cancer incidence and survival in renal transplant patients: 35-year experience
Authors: M. Kontos, E. Riza, T. Tsiampalis, G. Kirkilesis, I. Bokos, D. Moris, M. Darema, A. Andriopoulos, A. Varletzidou, S. Vernadakis, C. Nikolaidis, S. Lionaki, X. Sarantzi, C. Anagnostopoulou, I. Boletis, G. Zavos
Journal: Annals of Oncology (2019)
Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
Authors: D. O'Malley, D. Richardson, I.B. Vergote, L. Gilbert, L.P. Martin, G.M. Mantia-Smaldone, C. Castro, D. Provencher, U.A. Matulonis, K. Malek, K.N. Moore
Journal: Annals of Oncology (2019)
Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA
Authors: N. Delanoy, D. Robbrecht, K. Fizazi, F. Mercier, O. Sartor, R. De Wit, S. Oudard
Journal: Annals of Oncology (2019)